174
Participants
Start Date
November 13, 2017
Primary Completion Date
June 30, 2023
Study Completion Date
June 30, 2023
AMG 701
Subjects will receive IV infusions of AMG 701.
Pomalidomide
Subjects will receive oral capsules of pomalidomide.
Dexamethasone
Subjects will receive IV injections or oral dexamethasone.
Peter MacCallum Cancer Centre, Melbourne
The Alfred Hospital, Melbourne
Princess Alexandra Hospital, Woolloongabba
Columbia University Medical Center, New York
New York Presbyterian Hospital, Weill Cornell Medical College, New York
Universitätsklinikum Schleswig Holstein Campus Kiel, Kiel
Wake Forest Baptist Health, Winston-Salem
Levine Cancer Institute, Charlotte
Winship Cancer Institute Emory U, Atlanta
Mayo Clinic Florida, Jacksonville
The Medical College of Wisconsin, Milwaukee
Mayo Clinic, Rochester
University of Chicago Medical Center - Multiple Myeloma Research Consortium, Chicago
Washington University, St Louis
Universitätsklinikum Heidelberg, Heidelberg
University of Arkansas for Medical Sciences Myeloma Institute Slot 816, Little Rock
University of Texas MD Anderson Cancer Center, Houston
University of Utah Huntsman Cancer Institute, Salt Lake City
Mayo Clinic - Arizona, Scottsdale
Universitaetsklinikum Wuerzburg, Würzburg
Dana Farber Cancer Institute, Boston
Hackensack University Medical Center, Hackensack
Icahn School of Medicine at Mount Sinai, Hackensack
University Health Network-Princess Margaret Cancer Centre, Toronto
McGill University Health Centre Glen Site, Montreal
Nagoya City University Hospital, Nagoya
Gunma University Hospital, Maebashi
Kobe City Medical Center General Hospital, Kobe
Kanazawa University Hospital, Kanazawa
National Hospital Organization Okayama Medical Center, Okayama
The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku
Universitair Medisch Centrum Groningen, Groningen
Maastricht Universitair Medisch Centrum, Maastricht
Universitair Medisch Centrum Utrecht, Utrecht
Lead Sponsor
Amgen
INDUSTRY